EGFR/HER1/ERBB1
Alpha Lifetech can provide EGFR/HER1/ERBB1 corresponding products, help each customer's research and development.
01
Introduction To EGFR/HER1/ERBB1
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein, which is related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to EGFR/HER1/ERBB1 protein is a common target in medicine.
EGFR (epidermal growth factor receptor) is a transmembrane tyrosine kinase receptor located in the cell membrane, which is an important member of the family of tyrosine kinase receptors, which also includes HER-2 / NEU, HER-3, and HER-4. The EGFR gene is located on the short arm of p12-13 of human chromosome 7, contains 28 exons, and has a molecular weight of 170k Da.EGFR structure consists of three parts: extracellular domain (N terminus), membrane penetrating domain (hydrophobic α helix), and intracellular domain (C terminus).
Function of Target EGFR/HER1/ERBB1
Activation of EGFR can promote the growth and differentiation of many cells, including embryonic development, maintenance and repair of adult tissues, and proliferation and metastasis of cancer cells. EGFR is one of the key proteins involved in the information transmission between parental cancer cells and bystander cells in the tumor microenvironment. EGFR is responsible for the maintenance and function of cancer stem cells (CSCs), including stemness, metabolism, immunomodulatory activity, dormancy, and therapeutic resistance. EGFR regulates these pathways through multiple signaling cascades and often cooperates with other RTKs to exert further control roles.
Gene Pathway of Target EGFR/HER1/ERBB1
The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation by binding one of the ligands. The receptor is located on the cell surface, and the binding of the ligand activates the tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates many intracellular substrates, activating pathways leading to cell growth, DNA synthesis, and expression of oncogenes (such as fos and jun). EGFR activates the JAK / STAT pathway, promotes nuclear transport, stimulates mitosis, and enables the transcription of genes involved in proliferation, leading to cell proliferation and inhibition of apoptosis. Activation of the PI3K / Akt pathway by EGFR mediates cell survival.
Fig 1: EGFR Gene Pathway. (Reference source: Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017 Jul 25;8(30):50209-50220.)
Alpha Lifetech Can Provide
At present, various drugs targeting EGFR/HER1/ERBB1 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. EGFR/HER1/ERBB1 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, EGFR/HER1/ERBB1 protein products are also essential. Alpha Lifetech can provide EGFR/HER1/ERBB1 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
Reference
[1] XSabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020;20(10):815-834.
[2] Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997 Dec;8(12):1197-206.
[3] Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget. 2017 Jul 25;8(30):50209-50220.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102